-
公开(公告)号：EP2262492A2
公开(公告)日：2010-12-22
申请号：EP09719106.8
申请日：2009-03-03
申请人： Amgen Inc. , Yale University
IPC分类号： A61K31/138 , A61K45/06 , A61P1/04
CPC分类号： A61K31/138 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods for treating or preventing hyperacidic disorders such as GERD or NERD using calcium receptor active compounds.
-
2.发明公开CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY 审中-公开FOR USE钙剂节点在EPITHELVERLETZUNGEN的治疗
公开(公告)号：EP2278961A2
公开(公告)日：2011-02-02
申请号：EP09725557.4
申请日：2009-03-27
申请人： Amgen, Inc , Yale University
发明人： GEIBEL, John, Peter , MARTIN, David , NG, Gordon , RICHARDS, William, G. , VINEY, Joanne, L. , HERBERT, Patricia, R.
IPC分类号： A61K31/137 , A61K31/135 , A61K31/42 , A61K31/427 , A61K31/428 , A61P1/00
CPC分类号： A61K31/135 , A61K31/137 , A61K31/42 , A61K31/427 , A61K31/428
摘要： This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.
-
公开(公告)号：EP2139462B1
公开(公告)日：2014-01-22
申请号：EP08742406.5
申请日：2008-03-31
IPC分类号： A61K31/137 , A61K31/42 , A61K31/427 , A61K31/428 , A61K31/44 , A61P1/00
CPC分类号： A61K31/137 , A61K31/42 , A61K31/427 , A61K31/428 , A61K31/44
-
公开(公告)号：EP1937233B1
公开(公告)日：2013-01-09
申请号：EP06813808.0
申请日：2006-08-28
IPC分类号： A61K31/135 , A61P1/12
CPC分类号： A61K31/135 , A61K31/00 , A61K31/137 , A61K31/17 , A61K31/18 , A61K31/195 , A61K31/277 , A61K31/40 , A61K31/44 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/481 , Y02A50/491
摘要： The present invention relates to methods for treating intestinal fluid balance disorders and modulating intestinal fluid secretion and absorption using calcimimetics and calcilytics.
-
公开(公告)号：EP1948220A2
公开(公告)日：2008-07-30
申请号：EP06836438.9
申请日：2006-10-20
申请人： Amgen Inc.
IPC分类号： A61K38/20 , A61K39/395 , A61P9/10
CPC分类号： C07K16/245 , A61K38/1709 , A61K2039/505 , C07K16/2866 , C07K2319/30
摘要： The present invention relates to methods of decreasing, inhibiting, or preventing vascular calcification in subjects by administering IL-1 inhibitors. IL-1 inhibitors useful in this invention include anakinra, IL-1 antibodies, IL-1RI antibodies, IL-1 trap molecules, soluble IL-1 receptors, and anti-IL-1/IL-1R peptides and peptibodies.
-
公开(公告)号：EP1858553A2
公开(公告)日：2007-11-28
申请号：EP06738716.7
申请日：2006-03-17
申请人： Amgen Inc.,
CPC分类号： A61K31/13 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/195 , A61K31/277 , A61K31/36 , A61K2300/00
摘要： The present invention relates to methods of treating vascular calcification in subjects using calcimimetics.
-
公开(公告)号：EP2139462A2
公开(公告)日：2010-01-06
申请号：EP08742406.5
申请日：2008-03-31
IPC分类号： A61K31/137 , A61K31/42 , A61K31/427 , A61K31/428 , A61K31/44 , A61P1/00
CPC分类号： A61K31/137 , A61K31/42 , A61K31/427 , A61K31/428 , A61K31/44
摘要： The present invention relates to methods for treating or preventing bowel disorders using calcimimetics.
-
8.发明公开
公开(公告)号：EP1937233A2
公开(公告)日：2008-07-02
申请号：EP06813808.0
申请日：2006-08-28
IPC分类号： A61K31/135 , A61P1/12
CPC分类号： A61K31/135 , A61K31/00 , A61K31/137 , A61K31/17 , A61K31/18 , A61K31/195 , A61K31/277 , A61K31/40 , A61K31/44 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/481 , Y02A50/491
摘要： The present invention relates to methods for treating intestinal fluid balance disorders and modulating intestinal fluid secretion and absorption using calcimimetics and calcilytics.
-
9.发明授权METHODS FOR TREATMENT OF PATIENTS AFFLICTED WIH MULTIPLE SCLEROSIS USING CONSENSUS INTERFERON 失效对于有多个病人的处理方法硬化协商一致干扰素痛苦
公开(公告)号：EP1003546B1
公开(公告)日：2006-09-06
申请号：EP98933344.8
申请日：1998-07-15
申请人： Amgen Inc.,
发明人： MARTIN, David , FISCHER, Norman, L.
CPC分类号： A61K38/212 , A61K2300/00
摘要： The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con, either alone or in combination with another active agent.
-
公开(公告)号：EP0792160B1
公开(公告)日：2001-09-05
申请号：EP95935548.8
申请日：1995-11-13
申请人： Amgen Inc.
发明人： MARTIN, David
IPC分类号： A61K38/18
CPC分类号： A61K38/185
摘要： The present invention is directed to the use of glial-derived neurotrophic factor (GDNF) to inhibit or prevent seizure activity. The methods of the present invention are accomplished by administering GDNF to patients having or potentially having a neurodegenerative disorder such as epilepsy. Pharmaceutical compositions containing a therapeutically effective amount of GDNF in a pharmaceutically acceptable carrier are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.014 秒)
